Alan Seth Krasner - Jan 19, 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: Chief Medical Officer
Signature: /s/ Marc Wilson, as attorney-in-fact
Stock symbol: CRNX
Transactions as of: Jan 19, 2022
Transactions value $: -$61,613
Form type: 4
Date filed: 1/21/2022, 03:54 PM
Next filing: Mar 2, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Options Exercise	$80.5K	+6.7K	+80.62%	$12.01	15K	Jan 19, 2022	Direct	F1, F2
transaction	CRNX	Common Stock	Sale	-$142K	-6.7K	-44.63%	$21.21	8.31K	Jan 19, 2022	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Non-qualified stock option (Right to Buy)	Options Exercise	$0	-6.7K	-4.01%	$0.00	160K	Jan 19, 2022	Common stock	6.7K	$12.01	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2	Includes 1,928 shares acquired under the Issuer's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person.
F3	Represents the weighted average sale price for the entire number of shares sold. The actual sales prices range between $20.77 and $21.68. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F4	Stock option granted June 16, 2018 with 25% vesting on the first anniversary of the grant date and the remainder vesting in a series of thirty-six (36) successive equal monthly installments thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.